NextCore -TCR a generic resource for therapeutic T cell receptor discovery (Skattefunn)

Offentlig prosjektsammendrag

Adoptive Cell Therapy (ACT) is in the forefront of novel cancer therapy. Chimeric antigen receptor (CAR), one form of ACT, has shown curative effect in hematological cancers. The big issue is now to develop therapies for solid cancers. In this space novel TCR based ACT, optimized for specificity and efficacy and lacking detrimental cross reactivity, will play an imperative role. The NextCore-TCR approach is designed to optimally address this huge unmet medical need. Nextera will establish and use the NextCore-TCR library for partnering with larger pharma and biotech companies. Nextera endeavor to be a solution provider to the TCR oncology market through partners in the field of ACT and TCR-drug modalities.